Drug Type Small molecule drug |
Synonyms Molixan, BAM-205, NOV-205 |
Target |
Action stimulants |
Mechanism NGFB stimulants(Beta-nerve growth factor stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Russia (10 Sep 2006), |
Regulation- |
Molecular FormulaC10H17N3O6S |
InChIKeyRWSXRVCMGQZWBV-WDSKDSINSA-N |
CAS Registry70-18-8 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Hepatitis B | Russia | 27 Oct 2006 | |
| Hepatitis C | Russia | 10 Sep 2006 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| COVID-19 | Phase 3 | Russia | 06 Mar 2021 | |
| Chronic hepatitis C genotype 1 | Phase 2 | United States | 01 Mar 2010 | |
| Radiation Injuries | Preclinical | United States | - |





